Olympus–Swan Deal Highlights Rise of Build-to-Buy in Robotic Surgery and Medtech
Olympus Corporation and Revival Healthcare Capital made headlines this week by formalizing a build-to-buy agreement. Under the terms, Olympus gains exclusive rights to acquire Swan EndoSurgical, a company it co-incubated with Revival to develop a next-generation robotic platform for endoluminal surgery. The potential price tag? Up to $458 million, starting with a $65 million initial investment from Olympus. This blog is originally published here: https://shorturl.at/LLE3n
Comentario
Compartir
